| Not Yet Recruiting | Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma NCT05411237 | AIDS Malignancy Consortium | Phase 3 |
| Not Yet Recruiting | Efficacy and Safety of Doravirine in the Rapid Initiation NCT07357584 | Fundación Huésped | Phase 4 |
| Not Yet Recruiting | A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT1 NCT06987318 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Not Yet Recruiting | Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication A NCT07081763 | ANRS, Emerging Infectious Diseases | Phase 2 |
| Not Yet Recruiting | Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression NCT05459077 | Duke University | N/A |
| Not Yet Recruiting | Combining Latency Reversing Agents to Address the HIV Reservoir NCT07384624 | Erasmus Medical Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE NCT07476339 | CAN Community Health | Phase 4 |
| Recruiting | Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States NCT07293559 | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | — |
| Recruiting | A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living With NCT07392372 | BioNTech SE | Phase 1 |
| Recruiting | HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study NCT07215468 | TaiMed Biologics Inc. | Phase 2 |
| Recruiting | A Phase Ⅱa Clinical Study of CL-197 Capsules NCT07308782 | Henan Genuine Biotech Co., Ltd. | Phase 2 |
| Recruiting | Safety Study of MucoCept-CVN NCT07181486 | Craig Cohen, MD, MPH | Phase 1 |
| Recruiting | Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance NCT06747507 | University of Nairobi | Phase 3 |
| Active Not Recruiting | Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV NCT07055451 | Gilead Sciences | Phase 1 |
| Terminated | Study of GS-1219 in Participants With HIV-1 NCT07115368 | Gilead Sciences | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by NCT06919016 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Not Yet Recruiting | Research on the Psychological Status of Patients With HIV-1 Infection NCT07080138 | Shanxi Bethune Hospital | — |
| Withdrawn | A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patient NCT05582694 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Recruiting | Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV NCT06554717 | Massachusetts General Hospital | Phase 2 |
| Suspended | A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX- NCT06905275 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Recruiting | Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir NCT06640192 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Phase 2 |
| Recruiting | Study of GS-3242 in Participants With HIV-1; Substudy-05 NCT07001319 | Gilead Sciences | Phase 1 |
| Recruiting | Pomalidomide as an Immune-enhancing Agent for the Control of HIV NCT06660498 | University of Aarhus | Phase 1 / Phase 2 |
| Withdrawn | CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy NCT06336434 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Recruiting | Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in P NCT06774872 | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | Phase 2 |
| Recruiting | Improving Coronary Vascular Health in Women NCT06843902 | Massachusetts General Hospital | Phase 2 |
| Recruiting | PERSON-CENTERED APPROACHES TO VIREMIA: CONNECTION, RAPPORT, AND ENGAGEMENT STUDY NCT07021092 | Centre for Infectious Disease Research in Zambia | N/A |
| Withdrawn | To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults NCT03149211 | United BioPharma | Phase 3 |
| Not Yet Recruiting | A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 NCT05222945 | ANRS, Emerging Infectious Diseases | N/A |
| Recruiting | Ending the Epidemic Interventions in the Dental Setting - UH3 NCT06890988 | Columbia University | N/A |
| Recruiting | Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Chil NCT06749054 | Gilead Sciences | Phase 2 |
| Not Yet Recruiting | Clinical Research on the Use of Immune Checkpoint Inhibitors Combined With Chidamide for the Functional Cure o NCT06902038 | Jun Chen, MD | N/A |
| Recruiting | Investigating the Optimal Management of Dolutegravir Resistance NCT06762054 | University of Nairobi | — |
| Recruiting | DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infec NCT06203132 | ANRS, Emerging Infectious Diseases | Phase 3 |
| Recruiting | Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers NCT06648629 | Syracuse University | N/A |
| Recruiting | Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa NCT06205602 | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Phase 2 |
| Recruiting | Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 NCT06532656 | Gilead Sciences | Phase 2 / Phase 3 |
| Not Yet Recruiting | Primary and Secondary Drug Resistance Mutations (DRMs) in HIV As a Risk Factor of Failure of ART, Including Tw NCT06661317 | Medical University of Warsaw | — |
| Not Yet Recruiting | Establishment of a Database of HIV Subjects Initiating or Simplifying Dual Therapy With Dolutegravir/Lamivudin NCT06637813 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Terminated | Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated NCT06613685 | Gilead Sciences | Phase 2 / Phase 3 |
| Active Not Recruiting | Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafen NCT06630286 | Gilead Sciences | Phase 3 |
| Active Not Recruiting | Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppress NCT06630299 | Gilead Sciences | Phase 3 |
| Not Yet Recruiting | Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in P NCT06580873 | Saskatchewan Health Authority - Regina Area | Phase 4 |
| Recruiting | Prevention ICONA Dedicated Ensemble NCT07186244 | Fondazione ICONA | — |
| Not Yet Recruiting | Analytical Treatment Interruption in a Patient With HIV Post Allogeneic Stem Cell Transplantation From a CCR5 NCT06582797 | University of Kansas Medical Center | N/A |
| Not Yet Recruiting | Immuno-virological Evaluation of Persons Living With HIV (PLWH) NCT05973825 | University Hospital, Ghent | N/A |
| Unknown | Studying Topiramate for Re-Activating the HIV-1 Reservoir NCT06282783 | Erasmus Medical Center | Phase 1 / Phase 2 |
| Recruiting | A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Stud NCT06337032 | Gilead Sciences | Phase 4 |
| Active Not Recruiting | Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Bikt NCT06544733 | Gilead Sciences | Phase 2 / Phase 3 |
| Recruiting | Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI NCT06602622 | Instituto Mexicano del Seguro Social | Phase 4 |
| Completed | Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study NCT06022406 | Jean-Pierre Routy | Phase 2 |
| Active Not Recruiting | B/F/TAF to DTG/3TC Switch Study NCT06444620 | University of Nairobi | Phase 3 |
| Recruiting | Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals NCT06507059 | Chang Gung Memorial Hospital | Phase 3 |
| Completed | Identification of Barriers and Facilitators of Implementation of the Out-of-Hospital Administration of the Lon NCT06643897 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | N/A |
| Withdrawn | Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia NCT05700630 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Recruiting | Triage Survey for Infectious Disease Eligibility NCT06492187 | Brooklyn Clinical Research | — |
| Completed | Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Sout NCT06393387 | Midway Specialty Care Center | — |
| Active Not Recruiting | Pausing Antiretroviral Treatment Under Structured Evaluation NCT06031272 | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Phase 1 |
| Not Yet Recruiting | Psychoeducation, Relaxation, PrOblem Solving, Activation, Cognitive Coping Therapy for Adolescents and Youth i NCT06247527 | University of Nairobi | N/A |
| Active Not Recruiting | IGHID 12230 - An Implementation Trial of an Experiential Brief Alcohol Intervention for HIV Prevention NCT06358885 | University of North Carolina, Chapel Hill | N/A |
| Recruiting | Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During NCT06071767 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Recruiting | Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservo NCT05668026 | University of Aarhus | Phase 1 / Phase 2 |
| Active Not Recruiting | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Trea NCT06333808 | Gilead Sciences | Phase 3 |
| Recruiting | Observational PIC Destination Cohort NCT05985642 | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | — |
| Not Yet Recruiting | A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir NCT04985890 | UBP Greater China (Shanghai) Co., Ltd | Phase 2 |
| Recruiting | Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Liv NCT05660980 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Withdrawn | Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpiviri NCT05156658 | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Phase 4 |
| Unknown | Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulatio NCT04620291 | United BioPharma | Phase 1 |
| Completed | Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) NCT06104306 | Gilead Sciences | Phase 4 |
| Unknown | The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients NCT04404049 | UBP Greater China (Shanghai) Co., Ltd | Phase 2 |
| Not Yet Recruiting | UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection NCT04406727 | United BioPharma | Phase 3 |
| Unknown | UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients NCT03164447 | United BioPharma | Phase 2 |
| Active Not Recruiting | 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults NCT05890963 | David Ho | Phase 1 |
| Active Not Recruiting | Group-Based Intervention to Improve Mental Health and Adherence Among Youth Living With HIV in Low Resource Se NCT04024488 | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | N/A |
| Active Not Recruiting | A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected Wi NCT05924438 | Professor Francois Venter | Phase 3 |
| Recruiting | PrEPsmart 2-1-1 Pilot NCT06631365 | Public Health Foundation Enterprises, Inc. | Phase 2 |
| Active Not Recruiting | Healthy Lifestyles: A Home Based Physical Activity Intervention in Persons Living With HIV NCT05896852 | Georgetown University | N/A |
| Completed | Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine NCT06185452 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Phase 4 |
| Withdrawn | Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission NCT05769569 | Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase 1 |
| Recruiting | Caspofungin for Pneumocystis Pneumonia in PLWHIV. NCT06691321 | Instituto Nacional de Enfermedades Respiratorias | — |
| Enrolling By Invitation | Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101 NCT05143307 | Excision BioTherapeutics | Phase 1 |
| Active Not Recruiting | Long-Acting Treatment in Adolescents (LATA) NCT05154747 | University College, London | Phase 3 |
| Completed | A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV NCT05630885 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Recruiting | A Clinical Trial of STP0404 in Adults With HIV-1 Infection NCT05869643 | ST Pharm Co., Ltd. | Phase 2 |
| Recruiting | Cannabis Use, Cognition, and the Endocannabinoid System in HIV NCT04883255 | University of California, San Diego | EARLY_Phase 1 |
| Completed | A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Tr NCT05828095 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Unknown | Optimising Cohorts for HIV Cure Interventions NCT05852301 | Bayside Health | — |
| Active Not Recruiting | DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) NCT05705349 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | SYV: A Mental Health Intervention to Improve HIV Outcomes in Tanzanian Youth NCT05374109 | Duke University | N/A |
| Completed | Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed NCT05642481 | Radboud University Medical Center | — |
| Active Not Recruiting | A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) W NCT05631093 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) W NCT05630755 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Testing the Efficacy and Mechanisms of an Adapted Resilience Building Intervention in People Aging With HIV NCT05314088 | University of Alabama at Birmingham | N/A |
| Terminated | Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1 NCT04480554 | University of Pennsylvania | Phase 2 |
| Completed | Improving HIV Prevention Among Adolescent Girls and Young Women (AGYW) in Uganda NCT05516602 | MRC/UVRI and LSHTM Uganda Research Unit | N/A |
| Completed | A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA NCT05601128 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 3 |
| Completed | The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Vol NCT04950530 | Chelsea and Westminster NHS Foundation Trust | Phase 1 |
| Unknown | Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults Wi NCT05506605 | Fundacion Clinic per a la Recerca Biomédica | Phase 4 |
| Active Not Recruiting | Improving HIV-1 Control in Africa with Long Acting Antiretrovirals NCT05546242 | MRC/UVRI and LSHTM Uganda Research Unit | Phase 3 |
| Completed | Study of Novel Antiretrovirals in Participants With HIV-1 NCT05585307 | Gilead Sciences | Phase 1 |
| Completed | Quantification of Antisense HIV RNA in Patients NCT05381844 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Completed | Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART NCT05604209 | University of North Carolina, Chapel Hill | Phase 1 |
| Active Not Recruiting | The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events NCT05421286 | Rigshospitalet, Denmark | — |
| Enrolling By Invitation | Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containi NCT05584397 | University of Washington | — |
| Recruiting | Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT) NCT05136703 | Florida International University | N/A |
| Unknown | Advanced HIV: Outcomes for Rapid ART NCT05526118 | Valley AIDS Council | — |
| Active Not Recruiting | Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Re NCT05471076 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Recruiting | Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch NCT04892654 | Chelsea and Westminster NHS Foundation Trust | Phase 3 |
| Active Not Recruiting | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Trea NCT05502341 | Gilead Sciences | Phase 2 / Phase 3 |
| Completed | External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA NCT05495204 | Epividian | — |
| Completed | Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy NCT05433987 | Centre Hospitalier de Cannes Simone Veil | — |
| Completed | TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals NCT05275998 | TaiMed Biologics Inc. | Phase 1 / Phase 2 |
| Unknown | A Pilot Study to Evaluate Alternative Viral Load Tests During Start of Antiretroviral Therapy NCT05418790 | Luis Montaner | N/A |
| Active Not Recruiting | HIV Transmission in the Era of Scaling up Antiretroviral Therapy in Ethiopia NCT05652400 | Lund University | — |
| Completed | Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV NCT05330143 | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV NCT04174755 | University College Dublin | N/A |
| Completed | A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02) NCT04120415 | ANRS, Emerging Infectious Diseases | Phase 2 |
| Active Not Recruiting | Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologi NCT05220358 | Orlando Immunology Center | Phase 4 |
| Completed | Supporting Treatment Adherence for Resilience and Thriving (START) NCT05140876 | Florida International University | N/A |
| Completed | Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Wome NCT05281510 | Gilead Sciences | Phase 2 |
| Recruiting | Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE U NCT05129345 | Duke University | — |
| Unknown | Thetha Nami Ngithethe Nawe ("Let's Talk"): Step Wedge cRCT of Peer Led Community PrEP and SRH for Youth in Sou NCT05405582 | Africa Health Research Institute | N/A |
| Unknown | A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) NCT05414786 | International AIDS Vaccine Initiative | Phase 1 |
| Unknown | A Real-world Study of Lamivudine and Dotiravir Sodium Tablets in the Treatment-naïve HIV-1 Infected Patients NCT05332470 | Peking Union Medical College Hospital | — |
| Completed | Expedited Partner Therapy and the HIV Prevention Cascade NCT04553211 | University of California, Los Angeles | N/A |
| Completed | Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Supp NCT04738812 | ANRS, Emerging Infectious Diseases | Phase 3 |
| Completed | The Visceral Adiposity Measurement and Observation Study NCT05383456 | Theratechnologies | — |
| Completed | Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of NCT05165550 | Viriom | Phase 1 |
| Withdrawn | Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P) NCT03834909 | Johns Hopkins University | Phase 1 |
| Unknown | Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care NCT05204394 | Viriom | Phase 2 / Phase 3 |
| Completed | HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV NCT05481216 | NEAT ID Foundation | — |
| Terminated | Implementing Cabenuva in Arkansas HIV Programs NCT05096949 | University of Arkansas | N/A |
| Active Not Recruiting | Uganda PrEP and Harm Reduction Evaluation NCT05040308 | University of Washington | N/A |
| Completed | BFTAF Elderly Switch Study NCT05243602 | University of Nairobi | Phase 4 |
| Completed | Longer-Acting PrEP in Transgender and Gender Diverse Texans NCT05044286 | University of Texas at Austin | — |
| Completed | HIV-Infected Latin American Asylum Seekers in Europe: Insights From the EuroLatin HIV Cohort NCT05998499 | Hospital Universitario Infanta Leonor | — |
| Completed | Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART NCT05144386 | Excision BioTherapeutics | Phase 1 |
| Unknown | BCG Vaccination Effect on Latent Reservoir Size in Treated HIV-1 Infection: NCT05004038 | University of Zurich | Phase 2 |
| Unknown | Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 In NCT05122754 | Shanghai Public Health Clinical Center | Phase 4 |
| Completed | A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoi NCT05056974 | United BioPharma | Phase 2 |
| Recruiting | HIV Resistance, Molecular Epidemiology and New Treatment Strategies in the Eastern European Region and in Russ NCT06127290 | Euresist Network GEIE | — |
| Active Not Recruiting | Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppre NCT05052996 | Gilead Sciences | Phase 2 |
| Active Not Recruiting | Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodefic NCT04776252 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder NCT04963712 | Shanghai Public Health Clinical Center | EARLY_Phase 1 |
| Unknown | Impact of V106I on Resistance to Doravirine NCT04894357 | Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental | — |
| Completed | Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experi NCT04388904 | The Crofoot Research Center, Inc. | Phase 4 |
| Unknown | A Study to Test Three Experimental HIV Vaccines in Healthy Adults. NCT04553016 | University of Oxford | Phase 1 |
| Completed | 2000HIV Trained Innate Immunity in HIV Elite Controllers NCT04968717 | Radboud University Medical Center | — |
| Completed | Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg) NCT05030025 | Mylan Inc. | EARLY_Phase 1 |
| Completed | DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: NCT04884139 | Fundacion SEIMC-GESIDA | Phase 4 |
| Unknown | Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection NCT04296695 | Peking Union Medical College Hospital | Phase 4 |
| Unknown | Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age NCT05147740 | Tulika Singh, MD | Phase 4 |
| Unknown | Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutri NCT05051163 | Makerere University | Phase 2 / Phase 3 |
| Completed | Impact of Rapid ART Initiation on Retention in Care in the Southern US NCT04266938 | University of Louisville | N/A |
| Active Not Recruiting | A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands NCT04888754 | Erasmus Medical Center | — |
| Completed | Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection NCT04050735 | Brown University | N/A |
| Completed | Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 NCT04880395 | Fundación Huésped | Phase 4 |
| Completed | SARS-CoV-2 (COVID-19) Antibody PrevalencE in an Adult London HIV Cohort NCT05067400 | Royal Free Hospital NHS Foundation Trust | — |
| Unknown | ANRS 12406 EvvA Study NCT04593979 | ANRS, Emerging Infectious Diseases | — |
| Completed | InTSHA: Interactive Transition Support for HIV-infected Adolescents Using Social Media NCT03624413 | Emory University | N/A |
| Completed | Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Vi NCT04811040 | Gilead Sciences | Phase 1 |
| Unknown | Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in P NCT04860063 | Hospital Civil de Guadalajara | Phase 3 |
| Unknown | Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study) NCT04979468 | Societa' Italiana Di Malattie Infettive E Tropicali | Phase 3 |
| Completed | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in He NCT04802811 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | D²EFT Graphical Informed Consent NCT04668443 | Kirby Institute | — |
| Completed | Contingency Management for PrEP Adherence and/or Methamphetamine Use NCT04563962 | University of California, Los Angeles | N/A |
| Completed | Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Supp NCT04564547 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HI NCT04661813 | Case Western Reserve University | N/A |
| Active Not Recruiting | Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV NCT04255849 | Weill Medical College of Cornell University | Phase 3 |
| Unknown | ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavire NCT04429152 | Professor Francois Venter | Phase 3 |
| Active Not Recruiting | Simplifying Treatment and Monitoring for HIV (STREAM HIV) NCT04341779 | University of Washington | N/A |
| Completed | An Open-label Clinical Study of the Pharmacokinetics and Safety of Elsulfavirine, 200 mg Tablets, With Single NCT05148754 | Viriom | Phase 1 |
| Completed | Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HI NCT05163535 | Viriom | Phase 1 / Phase 2 |
| Unknown | Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis). NCT04526977 | Asociacion para el Estudio de las Enfermedades Infecciosas | — |
| Completed | DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV NCT04433780 | Professor Francois Venter | Phase 3 |
| Unknown | HIV Drug Resistance Pattern Due to Migration in Poland NCT04636736 | Medical University of Warsaw | — |
| Completed | Effect of Methamphetamine on Residual Latent HIV Disease Study NCT03825536 | University of California, San Francisco | Phase 4 |
| Completed | Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulatio NCT04620304 | United BioPharma | Phase 1 |
| Completed | The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / F NCT05606055 | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Phase 4 |
| Completed | Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who NCT04295772 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotypin NCT04549467 | Fundacion IDEAA | Phase 4 |
| Withdrawn | Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compa NCT03813979 | Radboud University Medical Center | Phase 4 |
| Completed | Poor Sleep and Inflammation in HIV-Infected Adults NCT03848325 | University of Pittsburgh | N/A |
| Completed | Postpartum Pre-exposure Prophylaxis (PrEP) Study to Evaluate an Adherence Promotion Package for Postpartum Wom NCT04897737 | University of California, Los Angeles | N/A |
| Completed | Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance NCT04495348 | University of Colorado, Denver | — |
| Completed | Islatravir and Methadone Pharmacokinetics (MK-8591-029) NCT04568603 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Test and Treat Strategy in New HIV Diagnosis. NCT04416906 | Judit Pich Martínez | Phase 3 |
| Active Not Recruiting | Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment NCT03940521 | Centre Hospitalier Universitaire de Nīmes | — |
| Unknown | ANRS 12372 MODERATO Study NCT04022967 | ANRS, Emerging Infectious Diseases | Phase 3 |
| Completed | Contribution of Dolutegravir to Obesity and Cardiovascular Disease NCT04340388 | Augusta University | Phase 4 |
| Completed | Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES) NCT04568239 | Association de Recherche en Virologie et Dermatologie | — |
| Unknown | Telemedicine in HIV Care in Buenos Aires NCT04513496 | Fundacion Ibis | — |
| Unknown | Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD NCT04311944 | Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic | N/A |
| Unknown | Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed NCT04311957 | Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic | Phase 4 |
| Completed | Call for Life Youth ART Adherence Study NCT04718974 | Makerere University | N/A |
| Completed | More Than a Machine: Make Point-of-care HIV-1 Viral Load Testing Effective in Rural Uganda NCT04517825 | University of North Carolina, Chapel Hill | — |
| Unknown | Euphorbia Kansui and HIV/AIDS Functional Cure NCT04503928 | Shanghai Public Health Clinical Center | Phase 1 |
| Active Not Recruiting | Bictegravir in the Elderly Living With HIV (BICEP) NCT05064020 | State University of New York at Buffalo | — |
| Completed | Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective NCT04448158 | Association de Recherche en Virologie et Dermatologie | — |
| Unknown | Epidemiological and Clinical Description of Women Living With HIV in Selected Countries of Latin America NCT04605354 | Helios Salud | — |
| Unknown | Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-107 NCT03588715 | Luis Montaner | Phase 1 |
| Completed | REal-Life Cohort With DOlutegravir + LAmivudina NCT04638686 | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | — |
| Completed | Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruptio NCT04385875 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Phase 1 |
| Recruiting | 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial NCT04553081 | University Hospital, Ghent | Phase 4 |
| Unknown | Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA) NCT04354818 | Kirby Institute | — |
| Withdrawn | the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy i NCT04041362 | United BioPharma | Phase 2 |
| Completed | Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency NCT04233216 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites NCT04301661 | University of Colorado, Denver | — |
| Completed | Genotype-Informed Versus Empiric Management of VirEmia NCT04233242 | Swiss Tropical & Public Health Institute | N/A |
| Completed | Short Cycle Therapy in ART Regimens Containing Rilpivirine: Assessment of Patients' Satisfaction NCT04281459 | Azienda Ospedaliera Universitaria Integrata Verona | N/A |
| Completed | An Integrated Strategy to Support Antiretroviral Therapy and Pre-exposure Prophylaxis Adherence for HIV Preven NCT04330989 | University of North Carolina, Chapel Hill | N/A |
| Completed | Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and T NCT04233879 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals NCT04097925 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Phase 2 |
| Completed | Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals NCT04079452 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Phase 3 |
| Completed | Second-line Switch to Dolutegravir Study NCT04229290 | University of Nairobi | Phase 4 |
| Completed | Dolutegravir in Real Life in Lesotho NCT04238767 | Swiss Tropical & Public Health Institute | — |
| Completed | Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated NCT04133012 | ANRS, Emerging Infectious Diseases | N/A |
| Unknown | Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen NCT04155554 | Azienda Ospedaliera Universitaria Senese | Phase 3 |
| Completed | Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine NCT04538040 | Quest Clinical Research | Phase 4 |
| Completed | Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants NCT04027387 | TaiMed Biologics Inc. | Phase 1 |
| Completed | The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coa NCT04424264 | Professor Francois Venter | Phase 1 |
| Unknown | Reducing Antiretroviral Treatments NCT04051970 | ANRS, Emerging Infectious Diseases | Phase 3 |
| Completed | ART First-line Treatment Durability in Russia NCT04253119 | MSD Pharmaceuticals LLC | — |
| Completed | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Ag NCT04143594 | Gilead Sciences | Phase 2 |
| Active Not Recruiting | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background NCT04150068 | Gilead Sciences | Phase 2 / Phase 3 |
| Completed | Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine NCT03961438 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1 |
| Completed | Estrogen, Probiotics and Vaginal Health to Prevent HIV Infection in ACB Women NCT03837015 | McMaster University | Phase 1 |
| Terminated | A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human I NCT04138199 | AbbVie | — |
| Completed | A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women NCT04094870 | University of North Carolina, Chapel Hill | Phase 4 |
| Completed | Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD NCT04050449 | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | — |
| Completed | Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Subst NCT03998176 | University of Nebraska | Phase 4 |
| Completed | Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Imm NCT04003103 | Merck Sharp & Dohme LLC | Phase 2 |
| Withdrawn | Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) NCT03549689 | Philip Grant | Phase 2 |
| Unknown | Self-testing for HCV Re-infection in MSM NCT04004299 | Erasmus Medical Center | N/A |
| Completed | Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bicteg NCT04009057 | Gilead Sciences | — |
| Terminated | Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutat NCT04040075 | Southampton Healthcare, Inc. | Phase 4 |
| Suspended | Pyridostigmine as Immunomodulator in People Living With HIV NCT03312244 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 2 |
| Completed | Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus ( NCT03960645 | Gilead Sciences | Phase 1 |
| Unknown | Quality of Life of Taiwan People Living With HIV NCT04063306 | Taiwan AIDS Nurse Society | — |
| Completed | Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM NCT03927313 | University of Cape Town | Phase 2 |
| Completed | Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection NCT03913195 | TaiMed Biologics Inc. | Phase 3 |
| Withdrawn | Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot NCT05295394 | Pedro Cahn | Phase 4 |
| Terminated | Pharmacokinetics and Safety of SAR441236 NCT03705169 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa NCT04066036 | Massachusetts General Hospital | — |
| Completed | Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients NCT04002323 | University Hospital Virgen de las Nieves | — |
| Completed | Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV NCT03837756 | University of Aarhus | Phase 2 |
| Unknown | Latent HIV-1, Viral Suppress and Hope for HIV Cure NCT04938518 | Kenya Medical Research Institute | — |
| Completed | B/F/TAF Switch Study for HIV-HBV Coinfection NCT03797014 | University of Maryland, Baltimore | Phase 4 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral NCT03859739 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Prospective Observational Cohort HIV & STI Study in Europe NCT03866759 | Hendrik Streeck | — |
| Completed | Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Co NCT03844386 | University of North Carolina, Chapel Hill | Phase 1 |
| Completed | 10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults NCT03875209 | David Ho | Phase 1 |
| Completed | mHealth for ART Adherence by HIV+ African Americans NCT04557332 | Environment and Health Group, Inc. | Phase 2 |
| Unknown | Clinical Epidemiology Cohort Study for Patient Living With HIV NCT04061889 | Kaohsiung Veterans General Hospital. | — |
| Completed | Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens NCT03816137 | Imperial College London | Phase 1 |
| Terminated | An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection NCT02972450 | ANRS, Emerging Infectious Diseases | Phase 1 / Phase 2 |
| Completed | High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial NCT05306704 | University of the Punjab | Phase 3 |
| Completed | Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Perso NCT03803605 | University of North Carolina, Chapel Hill | Phase 1 |
| Completed | IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth a NCT03416790 | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | — |
| Completed | Social Media for ART Adherence and Retention in Adolescents and Young Adults: the Vijana-SMART Study NCT05634265 | University of Washington | N/A |
| Completed | Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, NCT04173819 | International AIDS Vaccine Initiative | Phase 1 / Phase 2 |
| Completed | Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Dose NCT03706911 | Viriom | Phase 1 |
| Completed | A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymph NCT03593187 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Completed | HIV, Immune Activation and Salt Sensitive Hypertension NCT04459741 | Mulungushi University | N/A |
| Completed | Effect of Dolutegravir Intensification on HIV-1 Reservoirs NCT05351684 | University of Liege | Phase 2 |
| Unknown | Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects NCT03719664 | Frontier Biotechnologies Inc. | Phase 2 |
| Unknown | Metformin and Systemic Inflammation in HIV NCT03774108 | Hospital Civil de Guadalajara | Phase 4 |
| Completed | The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients NCT03743376 | United BioPharma | Phase 2 |
| Completed | Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously NCT03739866 | Gilead Sciences | Phase 1 |
| Completed | EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED NCT03683524 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Phase 4 |
| Completed | Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Othe NCT03709355 | Viriom | Phase 1 |
| Completed | Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bicteg NCT03580668 | Gilead Sciences | — |
| Completed | Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therap NCT05349838 | NEAT ID Foundation | Phase 3 |
| Recruiting | PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01) NCT03729752 | University of California, San Francisco | Phase 1 |
| Terminated | B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults NCT03532425 | University of Alberta | Phase 4 |
| Completed | Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection NCT03512210 | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Phase 4 |
| Completed | MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) NCT03552536 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to NCT03706898 | Viriom | Phase 1 |
| Completed | MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy NCT03570918 | MacroGenics | Phase 1 |
| Unknown | Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected P NCT03536234 | Immune System Regulation AB | Phase 2 |
| Completed | Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a NCT03631732 | Gilead Sciences | Phase 3 |
| Completed | Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutati NCT03512795 | Centre Hospitalier Universitaire Dijon | — |
| Unknown | Darunavir and Rilpivirine Interactions With Levonorgestrel Implant NCT03589027 | Makerere University | Phase 2 |
| Completed | Therapeutic Vaccination in Treated HIV Disease NCT03606213 | Steven Deeks | Phase 1 / Phase 2 |
| Completed | Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretro NCT03646370 | Thomas Jefferson University | — |
| Unknown | Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine NCT03567304 | Chiang Mai University | Phase 4 |
| Completed | PRO 140 in Treatment-Experienced HIV-1 Subjects NCT03902522 | CytoDyn, Inc. | Phase 2 / Phase 3 |
| Completed | Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrat NCT03706924 | Viriom | Phase 1 |
| Completed | Kenya HIV Self-Testing in PrEP Delivery NCT03593629 | University of Washington | N/A |
| Unknown | Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PH NCT04225325 | ADRIANO LAZZARIN, MD | Phase 4 |
| Terminated | Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppre NCT03333083 | Judit Pich | Phase 3 |
| Completed | Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudi NCT03311945 | Judit Pich | Phase 3 |
| Completed | LRAs United as a Novel Anti-HIV Strategy. NCT03525730 | Erasmus Medical Center | Phase 1 / Phase 2 |
| Completed | Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 NCT03360682 | Fundacion Clinic per a la Recerca Biomédica | Phase 4 |
| Completed | Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV NCT03329560 | The University of Texas Health Science Center, Houston | Phase 1 |
| Terminated | Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infec NCT03472326 | Gilead Sciences | Phase 2 |
| Recruiting | Pharmacokinetics Distribution of Raltegravir by PET/MR NCT03174977 | University of California, San Francisco | EARLY_Phase 1 |
| Withdrawn | Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant NCT03118661 | Washington University School of Medicine | Phase 1 |
| Unknown | Post-approval Observational Study of Elpida® in the First Line Therapy for HIV-1 Infected Patients With Backgr NCT03706950 | Viriom | — |
| Completed | Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen NCT03405935 | Gilead Sciences | Phase 3 |